INTRODUCTION
Adenocarcinoma is the commonest neoplasm affecting the duodenum. 1, 2 However; duodenal adenocarcinoma is rare and accounts for only 0.3% of all gastrointestinal malignancies. 3, 4 Surgical resection is the only potentially curative option in patients with localized disease, and pancreatico-duodenectomy (PD) is the procedure of choice for periampullary tumours, but is associated with significant morbidity and mortality. 5 For tumours distant from the ampulla, pancreas sparing partial duodenectomy (PSD) may be an alternative approach and has been advocated due to potentially lower morbidity than PD. 6 While PSD provides adequate tumour clearance, but avoids extensive dissection, which may affect adequate lymph node clearance. 6 But some authors reported similar lymph node clearance with both PSD and PD for distal duodenal tumours and less lymph node clearance with PSD than PD for proximal duodenal tumours. 7 However, due to the relative rarity of duodenal adenocarcinoma, the available data concerning the outcomes after surgical resection are limited to case series, and there are very few reports comparing the longterm outcomes after PSD and PD.
The primary aim of this study was to compare whether pancreas sparing duodenectomy is a safer alternative and oncologically acceptable option for duodena cancers away from the ampulla when compared to standard pancreaticoduodenectomy in a consecutive series from a single centre. The secondary aim was to evaluate the impact of pathological variables, including lymph node yield and ratio on long-term survival.
METHODS
This was a retrospective analysis of a prospectively maintained institutional database. After institutional audit committee approval, all consecutive patients who underwent surgical resection of duodenal adenocarcinoma were identified over a period of 21 years (January 1993 to March 2014) and were selected for review. In our unit, the decision to perform pancreassparing duodenectomy instead of pancreaticoduodenectomy has been made intraoperatively by the operating surgeon, and was considered in patients with lesions distant from the ampulla when macroscopic tumour clearance was deemed possible. However, this was discussed in a multi-disciplinary meeting preoperatively with available imaging. Patients who had PSD were compared with patients who underwent PD who served as a control group. Patients' demographic details, co-morbidities, clinical presentation, part of the duodenum involved and the nature of surgery were collected.
Surgical technique
Following abdominal exploration, the hepatic flexure of the colon was retracted inferiorly and an extensive Kocher maneuver was performed, elevating the duodenum out of the retroperitoneum. Next, the attachments at the ligament of treitz were divided, and the mesentery of the proximal jejunum was ligated and divided. The jejunum was then divided distal to the ligament of treitz, and the duodenojejunal specimen was passed beneath the superior mesenteric vessels to the right upper quadrant. The resection included the distal second portion of the duodenum as well as the third and fourth portions of the duodenum, as clinically indicated. At the proximal extent of the resection, the duodenum was divided. In most cases, the retained distal jejunum was delivered through a rent in the right transverse mesocolon, and a retrocolic duodenojejunostomy was performed in two layers. The duodenojejunostomy was often performed in end-to-side fashion, although other anatomic arrangements have been used (Figure 1 ).
A nasojejunal tube was placed distal to the anastomosis for postoperative feeding, if required and a tube drain was placed adjacent to the anastomosis. For proximal lesions after kocherisation the first and proximal second portions are removed along with distal stomach. Intestinal continuity was achieved with standard or Roux Y gastrojejunostomy ( Figure 2 ). Pancreatico-duodenectomy was performed as described elsewhere in the literature either classical or PPPD. All patients received standard postoperative care and lately ERAS protocol was introduced in our unit. 
Postoperative outcome
Postoperative complications were recorded according to Clavien-Dindo classification, and 90-day mortality was recorded. 8 Histological data were collated regarding tumour size, resection margin, number of lymph nodes involved and number of positive lymph nodes. Lymph node ratio (LNR) was calculated by dividing the total number of positive nodes by total number of lymph nodes harvested and survival with LNR of more than 0.2 and 0.3 were analyzed. Eligible patients received 5 FU based adjuvant treatment and details regarding postoperative chemotherapy and tumour recurrence were collected. Overall, disease free and disease specific survival was calculated for each group. If there were no follow up details available in our hospital system, then patients' general practitioners were contacted and last available follow up details were gathered.
Statistical methods
Continuous variables were compared between the two types of surgery using Mann-Whitney tests. Categorical variables were compared using Fisher's exact tests, with Kendall's Tau used where the categories were ordinal. Survival outcomes were assessed using Kaplan-Meier curves, with log-rank tests for comparisons between groups. Missing data were excluded on an analysis-byanalysis basis. All analyses were performed using IBM SPSS Statistics 22 (IBM Corp. Armonk, NY), with p<0.05 considered to be statistically significant.
RESULTS
Data were available for 79 patients, with a median age of 66 years (range: 26-86, quartiles: 55-71), of whom 43 (54%) were male. 19 (24%) underwent pancreas sparing duodenectomy (PSD) and 60 patients (76%) underwent pancreatico-duodenectomy (PD). Patient demographics were similar between groups (Table 1) . 55/60 patients (91%) in the PD group had proximal (first and second part) duodenal lesions compared to only 3/19 patients (17%) in the PSD group (p < 0.001). As expected, jaundice was more common in patients who underwent PD (22% vs. 0%, p = 0.031) and PSD patients more likely to present with vomiting (56% vs. 29%, p=0.050). Histological variables are compared in Table 2 . Tumour size (p=0.933), proportion of patients with lymph node metastases (stage III) (p=0.283), lymphovascular invasion (p=1.000), perineural invasion (p=0.0582) and tumour grade were similar in both groups. 54 patients (92%) in the PD group and 14 patients (78%) in the PSD group underwent an R0 resection (p=0.201). However, the median lymph node yield was significantly lower in the PSD group (6 vs. 17, p =< 0.001). At least six lymph nodes were resected in 91% of PD patients compared to only 39% of PSD patients (p<0.001). The lymph node ratio (LNR) was found to be similar in both groups, with medians of 0.10 and 0.05 respectively (p=0.478). This result remained consistent when treating LNR as a dichotomous variable, with no significant difference between the groups in the proportion of patients with LNR>0.2 (p=0.554) or >0.3 (p=1.000). Adjuvant chemotherapy details were available only for 39 patients, as a significant proportion of our patients receive adjuvant oncological treatment in another hospital.
Since the details on chemotherapy was not available for other patients' survival for patients with and without chemotherapy was not calculated. The overall median follow up period was 21 (IQR 9-54) months.
Short-term outcomes
Postoperative morbidity was not significantly different between groups (p=0.196); although anastomotic complications (all 20 leaks in the PD group were pancreatic leaks and 1 patient in the PSD group was duodeno-jejunostomy leak) were more common after PD (p=0.017) ( Table 3) . 90-day mortality (p=0.379) and median length of hospital stay (p=0.137) were also similar between groups (Table 4) . 20/29 (69%) 6/9 (67%) 1.000 *All anastomotic leaks in the PD group were related to the pancreatic anastomosis.
Long-term outcomes
Lymph node involvement was associated with a reduced disease-specific survival (DSS) after PD (p= 0.018), but did not impact on overall (OS) (p=0.084) or recurrence free (RFS) (p=0.194) survival. In the PSD group lymph node involvement did not affect these survivals (OS p= 0.519, DSS p= 0.886, RFS p= 0.499). Even though the numbers of lymph nodes resected were low in the PSD group, which is statistically significant (p≤0.001 for more than 6 and p=0.028 for more than 15 lymph nodes harvested), it did not affect the long-term survival. When compare the lymph node yield and survival (≤ 6 and >6, ≤15 and >15 lymph nodes harvested), the 1, 3 and 5 years OS, DSS and RFS were similar between the PSD and PD groups. Higher LNR was associated with significantly shorter overall, disease specific and recurrence free survival in PD patients. The overall long-term survival (overall, disease-specific and recurrence free survivals) were not significantly different between the groups.
(Tables 5-8, Figure 3 ). Data reported as Kaplan-Meier estimates of survival and numbers at risk. P-values are from Log-Rank tests, using all available followup. 9 The surgical management of duodenal pathology is challenging because of its retroperitoneal position and shared blood supply with the pancreas, and PD is the preferred option regardless of tumor site. 10, 11 Even though the mortality is decreasing with PD resection, the morbidity is still significantly high. 6 Our study suggest that pancreas-sparing partial duodenectomy, which avoids pancreatic anastomosis and thus pancreatic leak, is a feasible alternative for tumours not involving the ampulla, with comparable long-term results. 5, 12 Duodenal and periampullary lesions comparable due their anatomical location, shared blood supply, similar clinical presentation and association with hereditary syndromes. 13 Several series have demonstrated no survival difference between periampullary and duodenal malignancies. 5 Previous data on PSD have been limited to case reports or small cases series and there were no exhaustive data regarding the relationship between survival and type of surgical resection for duodenal carcinoma. 6 There were no study comparing the lymph node yield and their role in long-term survival in the management of duodenal carcinoma. This is the first larger study with 19 PSD for duodenal adenocarcinoma and compares the long-term outcomes of PSD and PD for duodenal adenocarcinoma. There are few larger studies describing PSD for duodenal carcinoma. Maher et al and Spalding etal showed median survival of 18.5 months and 56 months after PSD for adenocarcinoma, while Sohn et al showed 1,2,5 years survival of 76, 63, 0%. 5, 6, 14 The morbidity rates are reported as similar after PD and PSD for duodenal carcinoma. 15 However some authors reported higher morbidity associated with pancreas sparing duodenal resection than PD, although not significant. 16, 17 Pancreatic fistula, bleeding, abscess and delayed gastric emptying are some reported complications after duodenal resection either with PD or PSD .7 However pancreatic leak was reported to present in 33-66% of cases after PD and none with PSD. 15, 16 Our results showed 33% pancreatic fistula rate in the PD group, this is due to soft nature of the pancreas and smaller pancreatic duct associated with duodenal carcinoma compared with pancreatic tumours. 18 Spalding et al reported anastomotic leak (7%), bleeding and delayed gastric emptying as complications after PSD. 6 Maher et al showed 8% anastomotic leak, but on Sohn et al reported 30% anastomotic leak. 5, 14 They have also reported no pancreatic complications and less DGE occurred in the PSD group. 6 With advanced surgical techniques in highly specialised units the operative mortality of PD has been reported as 2-4%, while review on pancreas sparing resection has shown the mortality rate of 2%. 6 The high mortality observed after PD in this series may be attributed the long time period of the study, which dates back to 1993. 30-day mortality after pancreaticoduodenectomy in our unit in a contemporary series was 2.5%. 20 Even though PSD is an alternative option for PD in duodenal tumour resection; this can be associated with limited dissection, resection and low lymph node yield. Overman et al suggested poor outcome in small bowel adenocarcinoma associated with lymph node involvement. 21 5 years survival after surgery for duodenal carcinoma has been reported as 0% and 68% with and without lymph node involvement. 22, 23 However some authors found lymph node involvement did not show any significant difference in survival 24, 25 Thus, there is controversy regarding the lymph node status and survival in periampullary/duodenal carcinomas. Memorial SloanKettering Cancer Centre showed that nodal metastases, regardless of their location, do not have an impact on survival. Only resectability and the presence of non-nodal metastases predicts outcome. 26 Bakeen et al and Sarela et al suggested that lymph node invasion is a very important indicator for long term survival, more important than tumour size, or local invasion. 11, 27 Overman et al found that survival rates are related to total number of lymph nodes removed and number of positive lymph nodes. 21 Similar conclusions were obtained from several studies. In our series lymph node involvement showed poor disease specific survival in the PD group, but when comparing with PSD group there no difference in overall, disease specific and recurrence free survival.
The total number of lymph nodes to be removed in periampullary and pancreatic cancer has not yet been agreed. College of American Pathologist suggested 15 lymph nodes to be removed in exocrine pancreatic tumours. 28, 29 The minimum lymph node yield associated with an improved long-term survival after resection of periampullary carcinoma is in the range 10-16, but there is limited available data specifically relating to duodenal adenocarcinoma. 28, 30, 31 In this study, we evaluated cut-off values of 6 (median lymph node yield in PSD group) and 15 (CAP recommendation). Although there was a trend in favour of improved survival after PD in patients with a lymph node yield greater than six (Table 5-7) , this did not reach statistical significance, possibly due to a type II error. Our data has shown that although PSD is associated with a reduced lymph node yield compare to PD, this did not significantly impact on long-term survival. We did calculate the lymph node ratio for both PSD and PD patients, but this was not significant on comparison, though high ratio was associated with poor survival as described in the literature.
Lymph node ratio (LNR) has been shown to be an important prognostic factor after resection of pancreatic ductal adenocarcinoma and periampullary carcinomas. 32, 33 Several previously published series compared the LNR of 0.2, 0.3 and 0.4 and found that greater the LNR, the worse the prognosis. 28, 32 . We compared the survival for LNR of >0.2 and >0.3 within and between the groups. There were no patients with LNR of >0.4 in our group. Our results showed that LNR of >0.2 and >0.3 were associated with poor overall and recurrence free survival in the PD group, but this was not significant in the PSD group; this may be due to low statistical power. There was no significant difference in overall, recurrence free and disease specific survival when compared the LNR between PSD and PD groups (Tables 5-7) .
Adenocarcinoma of the duodenum is the least common type of periampullary tumour, but the prognosis is generally better than for carcinoma of the pancreas or distal bile duct. 34, 35 Hui-Ping Hsu et al. reported overall 5-year survival rate for periampullary carcinoma was 40.9% and the actuarial disease-specific 5-year survival rate was 45.7%. 36 And Katz et al reported 27% 5-year survival rate for pancreatic adenocarcinoma. 37 In a previous study of 13 patients who underwent PSD, five-year survival was significantly worse after PSD compared to PD (0% vs. 69%), and this was attributed to higher stage tumours in PSD patients. 5 In our data, the proportion of patients with Stage III-IV disease was similar between groups. There are 2 patients with stage 4 disease in our group who had PD, 1 had small cystic lesion in the ovary which was removed as it was thought as simple cyst and another patient had thick walled cystic lesion in the left lobe of liver, which was thought as cystadenoma. But histologically they were confirmed as metastases from duodenum.
Overman MJ reported no survival benefit from adjuvant chemotherapy following curative resection of duodenal adenocarcinoma. 38 This was confirmed by Duke University series in 2007, however the same series reported survival benefit with chemoradiotherapy only in the subgroup of patients who had negative resection margin (83% vs. 53%), though it was not statistically significant (p=0.07). 39 Even though we have the largest number of patients who had PSD for duodenal carcinoma, there are limitations due to retrospective nature of the study. Due to long period of inclusion during which advances in chemotherapy during the study period may affect the survival, but the authors do not believe that this would significantly influence our results, since the distribution of both procedures (PD and PSD) over the study period was similar. Multi-centre registry on management of duodenal carcinoma would help to capture accurate data in future.
CONCLUSION
We conclude that PSD is a feasible alternate option in patients with duodenal cancer. Certainly PD is associated with pancreatic leak, which is associated with significant mortality and this can be avoided with PSD. Despite a higher rate of positive margins, though not statistically significant, and a significantly lower lymph node harvest, similar survival outcomes can be achieved with PSD in patients with duodenal carcinoma not involving D2. 
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